Olivier De Henau
Overview
Explore the profile of Olivier De Henau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
863
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hirschhorn D, Budhu S, Kraehenbuehl L, Gigoux M, Schroder D, Chow A, et al.
Cell
. 2023 Mar;
186(7):1432-1447.e17.
PMID: 37001503
Cancer immunotherapies, including adoptive T cell transfer, can be ineffective because tumors evolve to display antigen-loss-variant clones. Therapies that activate multiple branches of the immune system may eliminate escape variants....
2.
Ghosh A, Michels J, Mezzadra R, Venkatesh D, Dong L, Gomez R, et al.
J Clin Invest
. 2022 Sep;
132(18).
PMID: 36106631
In addition to playing a major role in tumor cell biology, p53 generates a microenvironment that promotes antitumor immune surveillance via tumor-associated macrophages. We examined whether increasing p53 signaling in...
3.
Dubois-Vedrenne I, Al Delbany D, De Henau O, Robert V, Vernimmen M, Langa F, et al.
Oncotarget
. 2021 Sep;
12(19):1903-1919.
PMID: 34548907
Chemerin, a multifunctional protein acting through the receptor ChemR23/CMKLR1, is downregulated in various human tumors and was shown to display antitumoral properties in mouse models of cancer. In the present...
4.
Budhu S, Giese R, Gupta A, Fitzgerald K, Zappasodi R, Schad S, et al.
Cell Rep
. 2021 Jan;
34(2):108620.
PMID: 33440157
Phosphatidylserine (PS) is exposed on the surface of apoptotic cells and is known to promote immunosuppressive signals in the tumor microenvironment (TME). Antibodies that block PS interaction with its receptors...
5.
Dubois-Vedrenne I, De Henau O, Robert V, Langa F, Javary J, Al Delbany D, et al.
Front Oncol
. 2020 Jul;
10:977.
PMID: 32656083
[This corrects the article DOI: 10.3389/fonc.2019.01253.].
6.
Dubois-Vedrenne I, De Henau O, Robert V, Langa F, Javary J, Al Delbany D, et al.
Front Oncol
. 2019 Dec;
9:1253.
PMID: 31803622
Chemerin is a multifunctional protein acting mainly through the G protein-coupled receptor ChemR23/CMKLR1/Chemerin. Its expression is frequently downregulated in human tumors, including in melanoma and squamous cell carcinoma of the...
7.
De Henau O, Rausch M, Winkler D, Campesato L, Liu C, Cymerman D, et al.
Nature
. 2016 Nov;
539(7629):443-447.
PMID: 27828943
Recent clinical trials using immunotherapy have demonstrated its potential to control cancer by disinhibiting the immune system. Immune checkpoint blocking (ICB) antibodies against cytotoxic-T-lymphocyte-associated protein 4 or programmed cell death...
8.
De Henau O, Degroot G, Imbault V, Robert V, De Poorter C, Mcheik S, et al.
PLoS One
. 2016 Oct;
11(10):e0164179.
PMID: 27716822
Chemerin is a small chemotactic protein originally identified as the natural ligand of CMKLR1. More recently, two other receptors, GPR1 and CCRL2, have been reported to bind chemerin but their...
9.
Khalil D, Budhu S, Gasmi B, Zappasodi R, Hirschhorn-Cymerman D, Plitt T, et al.
Adv Cancer Res
. 2015 Jul;
128:1-68.
PMID: 26216629
Using the immune system to control cancer has been investigated for over a century. Yet it is only over the last several years that therapeutic agents acting directly on the...
10.
Bondue B, De Henau O, Luangsay S, Devosse T, de Nadai P, Springael J, et al.
PLoS One
. 2012 Jul;
7(6):e40043.
PMID: 22768214
Macrophages constitute a major component of innate immunity and play an essential role in defense mechanisms against external aggressions and in inflammatory responses. Chemerin, a chemoattractant protein, is generated in...